Literature DB >> 20154074

The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD.

Ramsey Sabit1, Paul Thomas, Dennis J Shale, Peter Collins, Seamus J Linnane.   

Abstract

BACKGROUND: It has been demonstrated that there is an increased risk of venous thromboembolism (VTE) during air travel on flights of long duration. Patients with COPD are also at increased risk of VTE, particularly during exacerbations, possibly because of a hypercoagulable state secondary to hypoxia and/or heightened systemic inflammation. We investigated the effects of hypoxia on indices of coagulation and systemic inflammation in patients with COPD.
METHODS: Twenty clinically stable patients with mild COPD were recruited. Patients were randomized to receive either medical air or 100% nitrogen through a 40% venturi mask at a flow rate of 10 L/min for 2 h. Blood was sampled for thrombin-antithrombin complex (TAT), prothrombin activation fragments 1 + 2 (F(1 + 2)), von Willebrand factor antigen (VWF:Ag), D-dimer, and interleukin-6 (IL-6) at baseline and after 2 h.
RESULTS: Patients in the hypoxia and control groups were similar in terms of age, sex, pack-years smoked, and severity of airflow obstruction. There was no difference in baseline TAT, F(1 + 2), VWF:Ag, D-dimer, or IL-6 levels between groups. In the control group, there was no change in markers of coagulation or systemic inflammation over the 2-h study. In patients who underwent hypoxic challenge, there was an increase in TAT (P < .001), F(1 + 2) (P < .01), and IL-6 (P < .01), whereas D-dimer and VWF:Ag levels were unchanged.
CONCLUSIONS: This study demonstrates that a 2-h hypoxic challenge in patients with COPD results in coagulation activation in conjunction with an increase in systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154074     DOI: 10.1378/chest.09-2764

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Translational and transcriptional responses in human primary hepatocytes under hypoxia.

Authors:  Gaya K Hettiarachchi; Upendra K Katneni; Ryan C Hunt; Jacob M Kames; John C Athey; Haim Bar; Zuben E Sauna; Joseph R McGill; Juan C Ibla; Chava Kimchi-Sarfaty
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-03-28       Impact factor: 4.052

2.  Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition.

Authors:  Anetta Undas; Milosz Jankowski; Przemysław Kaczmarek; Krzysztof Sladek; Kathleen Brummel-Ziedins
Journal:  Thromb Res       Date:  2011-05-31       Impact factor: 3.944

3.  Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry.

Authors:  Stefania Frasson; Gualberto Gussoni; Pierpaolo Di Micco; Raquel Barba; Laurent Bertoletti; Manuel J Nuñez; Beatriz Valero; Angel Luis Samperiz; Agustina Rivas; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

4.  The effects of sleep hypoxia on coagulant factors and hepatic inflammation in emphysematous rats.

Authors:  Jing Feng; Qing-shan Wang; Ambrose Chiang; Bao-yuan Chen
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

5.  Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure.

Authors:  Yasuhiro Hamatani; Moritake Iguchi; Michikazu Nakamura; Ryo Ohtani; Yugo Yamashita; Daisuke Takagi; Takashi Unoki; Mitsuru Ishii; Nobutoyo Masunaga; Hisashi Ogawa; Mio Hamatani; Mitsuru Abe; Masaharu Akao
Journal:  Heart Vessels       Date:  2015-07-29       Impact factor: 2.037

6.  Thrombin selectively engages LIM kinase 1 and slingshot-1L phosphatase to regulate NF-κB activation and endothelial cell inflammation.

Authors:  Antony Leonard; Catherine Marando; Arshad Rahman; Fabeha Fazal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-09-13       Impact factor: 5.464

7.  Benefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials.

Authors:  Mingjin Yang; Ying Xu; Hong Chen; Zhibo Xu; Fengming Luo
Journal:  Inflammopharmacology       Date:  2019-10-31       Impact factor: 4.473

8.  Clinical and Laboratory Findings of COVID-19 in High-Altitude Inhabitants of Saudi Arabia.

Authors:  Mostafa Abdelsalam; Raad M M Althaqafi; Sara A Assiri; Taghreed M Althagafi; Saleh M Althagafi; Ahmed Y Fouda; Ahmed Ramadan; Mohammed Rabah; Reham M Ahmed; Zein S Ibrahim; Dalal M Nemenqani; Ahmed N Alghamdi; Daifullah Al Aboud; Ahmed S Abdel-Moneim; Adnan A Alsulaimani
Journal:  Front Med (Lausanne)       Date:  2021-05-12

9.  Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia.

Authors:  Debjani Tripathy; Alma Sanchez; Xiangling Yin; Jinhua Luo; Joseph Martinez; Paula Grammas
Journal:  Front Aging Neurosci       Date:  2013-05-09       Impact factor: 5.750

10.  Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.

Authors:  Paul T King
Journal:  Clin Transl Med       Date:  2015-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.